Key facts
- Semaine (Pharmaceuticals)’s last known valuation is $6.5M (Feb 2021).
- It has raised $1.6M; the latest was Later Stage VC in Apr 2025.
- Notable investors include KarpReilly, Era VC, Ocampo Capital.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Semaine (Pharmaceuticals)
- ·The full record, as it builds
Funding rounds
No funding rounds for Semaine (Pharmaceuticals) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Semaine (Pharmaceuticals)
Provider of plant-based, anti-inflammatory supplements intended to provide relief from period pain. The company's supplements include plant-based vitamin capsules for bloating, cramps, mood, immune boosters, and skin care products, enabling customers to get personalized dietary supplements for their health care.
- Sector
- Consumer Products and Services (B2C)
- HQ
- New York, NY, United States
- Founded
- 2019
- Employees
- 10
- Website
- semainehealth.com/
- Ownership
- Privately Held (backing)
Semaine (Pharmaceuticals) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Semaine (Pharmaceuticals) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Semaine (Pharmaceuticals) in its N-PORT filings yet. We sweep new filings monthly.